Cristina Gasparetto, MD, Duke Cancer Institute
Advertisement
Articles by Cristina Gasparetto, MD, Duke Cancer Institute
Advertisement
Latest Updated Articles
Using IMiD-Based Strategies for Relapsed MyelomaPublished: August 3rd 2021 | Updated:
CAR T-Cell Therapy in RRMM: Adverse Event ManagementPublished: August 18th 2022 | Updated:
Improving Maintenance Therapy for MyelomaPublished: July 20th 2021 | Updated:
Improving Care in Multiple Myeloma: Unmet Needs and Future DirectionsPublished: August 25th 2022 | Updated:
CAR T-Cell Therapy: KarMMa Study and the Role of Ide-Cel in RRMMPublished: August 18th 2022 | Updated:
Treatment of Relapsed/Refractory Myeloma: Novel AgentsPublished: August 10th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5